Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide orodispersible tablet once-daily versus twice-daily dosing in adult eosinophilic esophagitis
2020-001314-37Phase 3Active
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in eosinophilic esophagitis (EoE) (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Proportion of patients with histological remission. Started Nov 2020; status: active.
02
Drugs
budesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2020-001314-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001314-37.